18 studies found for:    Empagliflozin | Phase 3
Show Display Options
Rank Status Study
1 Active, not recruiting Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: BI 10773 Placebo;   Drug: BI 10773 / BI 1356;   Drug: BI 10773 / BI 1356 Placebo
2 Active, not recruiting Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
Conditions: Diabetes Mellitus, Type 2;   Hyperglycemia
Interventions: Drug: Metformin 500 mg bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin low dose qd;   Drug: Empagliflozin high dose qd;   Drug: Empagliflozin low dose bid;   Drug: Empagliflozin high dose bid
3 Completed Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: BI 10773 high dose;   Drug: high dose FDC placebo;   Drug: linagliptin;   Drug: low dose FDC placebo;   Drug: high dose BI 10773 placebo;   Drug: BI 10773 low dose;   Drug: BI 10773 linagliptin FDC;   Drug: linagliptin placebo;   Drug: low dose BI 10773 placebo
4 Completed
Has Results
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo identical to BI10773 high dose;   Drug: BI 10773;   Drug: BI 10773 open label;   Drug: Placebo identical to BI10773 low dose;   Drug: Placebo identical to Sitagliptin 100mg;   Drug: BI10773;   Drug: Sitagliptin
5 Completed
Has Results
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: Placebo;   Drug: Sitagliptin 100mg
6 Completed
Has Results
Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo identical to BI 10773 high dose;   Drug: Placebo identical to BI 10773 low dose;   Drug: BI 10773
7 Active, not recruiting BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients.
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773 low dose;   Drug: Placebo BI 10773 high dose;   Drug: BI 10773 high dose;   Drug: Placebo BI 10773 low dose
8 Completed
Has Results
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
Conditions: Diabetes Mellitus, Type 2;   Hypertension
Interventions: Drug: Placebo;   Drug: BI 10773
9 Completed
Has Results
Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
Conditions: Diabetes Mellitus, Type 2;   Renal Insufficiency
Interventions: Drug: BI 10773;   Drug: Placebo
10 Completed Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: Empagliflozin
11 Completed
Has Results
Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: BI 10773
12 Completed
Has Results
Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Metformin;   Drug: BI 10773;   Drug: Placebo (low dose);   Drug: Placebo (high dose)
13 Not yet recruiting Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Empagliflozin;   Drug: Placebo;   Drug: Sitagliptin
14 Completed
Has Results
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
Conditions: Diabetes Mellitus, Type 2;   Obesity
Interventions: Drug: Placebo;   Drug: BI 10773
15 Recruiting Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin;   Drug: Empagliflozin + Linagliptin;   Drug: Empaglifozin placebo + Linagliptin placebo
16 Active, not recruiting Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773;   Drug: Glimepiride;   Drug: Placebo
17 Not yet recruiting 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
Conditions: Diabetes Mellitus, Type 2;   Hypertension
Interventions: Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
18 Enrolling by invitation Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea
Condition: Type 2 Diabetes
Intervention: Drug: BI 10773

Indicates status has not been verified in more than two years